Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chemomab Therapeutics Ltd ADR (CMMB)

Chemomab Therapeutics Ltd ADR (CMMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,509
  • Shares Outstanding, K 11,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,220 K
  • 60-Month Beta 0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.50
Trade CMMB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.12
  • Most Recent Earnings $-0.26 on 03/07/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6203 +24.13%
on 03/05/24
0.8800 -12.50%
on 03/13/24
+0.0923 (+13.62%)
since 02/27/24
3-Month
0.4600 +67.39%
on 01/25/24
0.8800 -12.50%
on 03/13/24
+0.2401 (+45.31%)
since 12/27/23
52-Week
0.4200 +83.33%
on 12/13/23
1.8900 -59.26%
on 05/19/23
-0.8500 (-52.47%)
since 03/27/23

Most Recent Stories

More News
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

─Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation, `Reinforcing and Extending Initial Study Results─ ─Provides New Insights...

CMMB : 0.7700 (+2.80%)
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

/PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of...

CMMB : 0.7700 (+2.80%)
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of...

CMMB : 0.7700 (+2.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV,...

See More

Key Turning Points

3rd Resistance Point 0.8800
2nd Resistance Point 0.8300
1st Resistance Point 0.8000
Last Price 0.7700
1st Support Level 0.7200
2nd Support Level 0.6700
3rd Support Level 0.6400

See More

52-Week High 1.8900
Fibonacci 61.8% 1.3285
Fibonacci 50% 1.1550
Fibonacci 38.2% 0.9815
Last Price 0.7700
52-Week Low 0.4200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar